TAC regimen: Difference between revisions
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
{{SK}}TAC; TAC Regimen; TAC regimen; Taxotere-Adriamycin-Cytoxan Regimen | {{SK}}TAC; TAC Regimen; TAC regimen; Taxotere-Adriamycin-Cytoxan Regimen | ||
==Overview== | ==Overview== | ||
Line 17: | Line 16: | ||
==Indications== | ==Indications== | ||
*[[Breast cancer]]<ref name="pmid19803960">{{cite journal| author=Martin M| title=Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer. | journal=Womens Health (Lond Engl) | year= 2006 | volume= 2 | issue= 4 | pages= 527-37 | pmid=19803960 | doi=10.2217/17455057.2.4.527 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19803960 }} </ref> | *[[Breast cancer]]<ref name="pmid19803960">{{cite journal| author=Martin M| title=Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer. | journal=Womens Health (Lond Engl) | year= 2006 | volume= 2 | issue= 4 | pages= 527-37 | pmid=19803960 | doi=10.2217/17455057.2.4.527 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19803960 }} </ref> | ||
Latest revision as of 17:59, 30 March 2015
WikiDoc Resources for TAC regimen |
Articles |
---|
Most recent articles on TAC regimen Most cited articles on TAC regimen |
Media |
Powerpoint slides on TAC regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on TAC regimen at Clinical Trials.gov Clinical Trials on TAC regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on TAC regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on TAC regimen Discussion groups on TAC regimen Patient Handouts on TAC regimen Directions to Hospitals Treating TAC regimen Risk calculators and risk factors for TAC regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for TAC regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:TAC; TAC Regimen; TAC regimen; Taxotere-Adriamycin-Cytoxan Regimen
Overview
TAC regimen refers to a regimen consisting of docetaxel (taxotere), doxorubicin and cyclophosphamide used in the adjuvant setting for the treatment of breast cancer.[1][2]
Regimen
TDocetaxel (Taxotere)
ADoxorubicin (Adriamycin)
CCyclophosphamide
Indications
References
- ↑ 1.0 1.1 Martin M (2006). "Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer". Womens Health (Lond Engl). 2 (4): 527–37. doi:10.2217/17455057.2.4.527. PMID 19803960.
- ↑ "NCI Thesaurus".